214 related articles for article (PubMed ID: 22945653)
1. Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays.
Gujral TS; Karp RL; Finski A; Chan M; Schwartz PE; MacBeath G; Sorger P
Oncogene; 2013 Jul; 32(29):3470-6. PubMed ID: 22945653
[TBL] [Abstract][Full Text] [Related]
2. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
Meyer AS; Miller MA; Gertler FB; Lauffenburger DA
Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085
[TBL] [Abstract][Full Text] [Related]
3. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.
Mackiewicz M; Huppi K; Pitt JJ; Dorsey TH; Ambs S; Caplen NJ
Breast Cancer Res Treat; 2011 Nov; 130(2):663-79. PubMed ID: 21814748
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer.
Yeh CY; Shin SM; Yeh HH; Wu TJ; Shin JW; Chang TY; Raghavaraju G; Lee CT; Chiang JH; Tseng VS; Lee YC; Shen CH; Chow NH; Liu HS
BMC Cancer; 2011 Apr; 11():139. PubMed ID: 21496277
[TBL] [Abstract][Full Text] [Related]
5. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.
Wu X; Zahari MS; Ma B; Liu R; Renuse S; Sahasrabuddhe NA; Chen L; Chaerkady R; Kim MS; Zhong J; Jelinek C; Barbhuiya MA; Leal-Rojas P; Yang Y; Kashyap MK; Marimuthu A; Ling M; Fackler MJ; Merino V; Zhang Z; Zahnow CA; Gabrielson E; Stearns V; Roa JC; Sukumar S; Gill PS; Pandey A
Oncotarget; 2015 Oct; 6(30):29143-60. PubMed ID: 26356563
[TBL] [Abstract][Full Text] [Related]
6. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.
Rankin EB; Fuh KC; Castellini L; Viswanathan K; Finger EC; Diep AN; LaGory EL; Kariolis MS; Chan A; Lindgren D; Axelson H; Miao YR; Krieg AJ; Giaccia AJ
Proc Natl Acad Sci U S A; 2014 Sep; 111(37):13373-8. PubMed ID: 25187556
[TBL] [Abstract][Full Text] [Related]
7. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
[TBL] [Abstract][Full Text] [Related]
8. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
[TBL] [Abstract][Full Text] [Related]
9. The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.
Antony J; Zanini E; Kelly Z; Tan TZ; Karali E; Alomary M; Jung Y; Nixon K; Cunnea P; Fotopoulou C; Paterson A; Roy-Nawathe S; Mills GB; Huang RY; Thiery JP; Gabra H; Recchi C
EMBO Rep; 2018 Aug; 19(8):. PubMed ID: 29907679
[TBL] [Abstract][Full Text] [Related]
10. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.
Linger RM; Cohen RA; Cummings CT; Sather S; Migdall-Wilson J; Middleton DH; Lu X; Barón AE; Franklin WA; Merrick DT; Jedlicka P; DeRyckere D; Heasley LE; Graham DK
Oncogene; 2013 Jul; 32(29):3420-31. PubMed ID: 22890323
[TBL] [Abstract][Full Text] [Related]
11. AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival.
Salian-Mehta S; Xu M; Wierman ME
Mol Cell Endocrinol; 2013 Jul; 374(1-2):92-100. PubMed ID: 23648337
[TBL] [Abstract][Full Text] [Related]
12. AXL-Driven EMT State as a Targetable Conduit in Cancer.
Antony J; Huang RY
Cancer Res; 2017 Jul; 77(14):3725-3732. PubMed ID: 28667075
[TBL] [Abstract][Full Text] [Related]
13. AXL is a potential target for therapeutic intervention in breast cancer progression.
Zhang YX; Knyazev PG; Cheburkin YV; Sharma K; Knyazev YP; Orfi L; Szabadkai I; Daub H; Kéri G; Ullrich A
Cancer Res; 2008 Mar; 68(6):1905-15. PubMed ID: 18339872
[TBL] [Abstract][Full Text] [Related]
14. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
[TBL] [Abstract][Full Text] [Related]
15. A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers.
Lee J; Kim S; Kim P; Liu X; Lee T; Kim KM; Do IG; Park JO; Park SH; Jang J; Hoe N; Harvie G; Kuller A; Jain A; Meyer G; Leesman G; Park YS; Choi MG; Sohn TS; Bae JM; Lim HY; Singh S; Kang WK
PLoS One; 2013; 8(1):e54644. PubMed ID: 23372746
[TBL] [Abstract][Full Text] [Related]
16. Cross-phosphorylation, signaling and proliferative functions of the Tyro3 and Axl receptors in Rat2 cells.
Brown JE; Krodel M; Pazos M; Lai C; Prieto AL
PLoS One; 2012; 7(5):e36800. PubMed ID: 22606290
[TBL] [Abstract][Full Text] [Related]
17. Comparative receptor tyrosine kinase profiling identifies a novel role for AXL in human stem cell pluripotency.
Son MY; Seol B; Han YM; Cho YS
Hum Mol Genet; 2014 Apr; 23(7):1802-16. PubMed ID: 24218367
[TBL] [Abstract][Full Text] [Related]
18. Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.
Wang C; Jin H; Wang N; Fan S; Wang Y; Zhang Y; Wei L; Tao X; Gu D; Zhao F; Fang J; Yao M; Qin W
Theranostics; 2016; 6(8):1205-19. PubMed ID: 27279912
[TBL] [Abstract][Full Text] [Related]
19. Axl receptor tyrosine kinase expression in breast cancer.
D'Alfonso TM; Hannah J; Chen Z; Liu Y; Zhou P; Shin SJ
J Clin Pathol; 2014 Aug; 67(8):690-6. PubMed ID: 24904064
[TBL] [Abstract][Full Text] [Related]
20. The crosstalk between AXL and YAP promotes tumor progression through STAT3 activation in head and neck squamous cell carcinoma.
Li J; Shi C; Zhou R; Han Y; Xu S; Ma H; Zhang Z
Cancer Sci; 2020 Sep; 111(9):3222-3235. PubMed ID: 32589311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]